drugset / Trial / NCT01777295

Development of Read-outs in Healthy, Hepatitis B Virus Naive Adults Vaccinated With the Hepatitis B Surface Antigen (HBsAg) in Combination With a GlaxoSmithKline (GSK) Biologicals' Adjuvant System

NCT01777295

RandomizedParallel-groupSingle-blindPrevention

Summary

This study aims to develop innovative immunological read-outs and new technologies in order to further characterise the early immune response and its kinetics as well as the adaptive immune responses to adjuvanted vaccines. This study will also evaluate the reactogenicity in healthy, hepatitis B virus naive adults vaccinated with the hepatitis B surface antigen in combination with a GSK Biologicals' Adjuvant System.

Timeline

Start
2013-02-25
Primary completion
2016-05-17
Completion
2016-09-13

Drugs

EvaluationDrugModalityDoseRoute
Comparator Engerix-B Vaccine Intramuscular
Subject GSK2231392A Vaccine Intramuscular